Fiscal Period | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Period End Date | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
Revenue | 4.05 | 20.39 | 16.78 | 10.02 |
Total Revenue | 4.05 | 20.39 | 16.78 | 10.02 |
Costof Revenue Total | 1.56 | 19.33 | 13.77 | 7.85 |
Gross Profit | 2.50 | 1.06 | 3.01 | 2.17 |
Selling/ General/ Admin Expenses Total | 0.08 | 0.20 | 0.18 | 0.01 |
Depreciation/ Amortization | 0.01 | 0.00 | 0.00 | 0.00 |
Other Operating Expenses Total | 4.06 | 4.59 | 1.37 | 1.21 |
Total Operating Expense | 5.70 | 24.13 | 15.32 | 9.07 |
Operating Income | -1.65 | -3.74 | 1.46 | 0.95 |
Interest Inc( Exp) Net- Non- Op Total | 0.00 | - | -0.05 | 0.00 |
Other Net | 2.26 | 6.02 | 0.00 | 0.00 |
Net Income Before Taxes | 0.61 | 2.28 | 1.46 | 0.95 |
Provisionfor Income Taxes | 0.16 | 0.67 | 0.37 | 0.24 |
Net Income After Taxes | 0.45 | 1.62 | 1.09 | 0.72 |
Net Income Before Extra Items | 0.45 | 1.62 | 1.09 | 0.72 |
Net Income | 0.45 | 1.62 | 1.09 | 0.72 |
Income Availableto Com Excl Extra Ord | 0.45 | 1.62 | 1.09 | 0.72 |
Income Availableto Com Incl Extra Ord | 0.45 | 1.62 | 1.09 | 0.72 |
Diluted Net Income | 0.45 | 1.62 | 1.09 | 0.72 |
Diluted Weighted Average Shares | 1.36 | 1.36 | 1.36 | 1.36 |
Diluted EPS Excluding Extra Ord Items | 0.33 | 1.19 | 0.80 | 0.53 |
Diluted Normalized EPS | 0.33 | 1.19 | 0.80 | 0.53 |
Total Adjustmentsto Net Income | - | - | 0.00 | - |
DPS- Common Stock Primary Issue | - | - | 0.00 | 0.00 |
EVOQ REMEDIES-MT Dividend EVOQ REMEDIES-MT Bonus EVOQ REMEDIES-MT News EVOQ REMEDIES-MT AGM EVOQ REMEDIES-MT Rights EVOQ REMEDIES-MT Splits EVOQ REMEDIES-MT Board Meetings EVOQ REMEDIES-MT Key Metrics EVOQ REMEDIES-MT Shareholdings EVOQ REMEDIES-MT Balance Sheet EVOQ REMEDIES-MT Cashflow EVOQ REMEDIES-MT Q1 Results EVOQ REMEDIES-MT Q2 Results EVOQ REMEDIES-MT Q3 Results EVOQ REMEDIES-MT Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks